Alpine Woods Capital Investors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Alpine Woods Capital Investors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-10,000	Closed	-$28K	–	423
2016 Q1	$28K	Hold	10,000	–	–	﹤0.01%	420
2015 Q4	$103K	Hold	10,000	–	–	0.01%	444
2015 Q3	$114K	Buy	+10,000	New	+$133K	0.01%	464

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Alpine Woods Capital Investors's BCRX Position: Q2 2016 in Review

Alpine Woods Capital Investors sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2016, closing a stake of 10,000 shares — an estimated $28K sold.

Alpine Woods Capital Investors first reported a position in BCRX in Q3 2015 and held it in 3 quarters. The position peaked at $114K in Q3 2015. 100 funds tracked by Wall St. Rank hold BCRX as of Q2 2016.

Alpine Woods Capital Investors reported no remaining BioCryst Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Alpine Woods Capital Investors sold 10,000 BioCryst Pharmaceuticals shares in Q2 2016, an estimated $28K.
Alpine Woods Capital Investors first reported a position in BioCryst Pharmaceuticals in Q3 2015 and held it in 3 quarters.
Alpine Woods Capital Investors's BioCryst Pharmaceuticals position peaked at $114K in Q3 2015.
100 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2016.

Based on Alpine Woods Capital Investors's 13F filing for Q2 2016, filed 10 Aug 2016.